Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 28 Suppl 1 (Suppl 1), S24-31

Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors

Affiliations
Review

Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors

A F Gazdar. Oncogene.

Abstract

The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.

Figures

Figure 1
Figure 1
Schematic of EGFR TK activation and EGFR kinase domain mutations. (a) Upon binding of the extracellular ligand, the EGFR receptor dimerizes, leading to the activation of cytoplasmic TK activity. (b) This exon boundary map shows the location of regions within the EGFR TK domain wherein mutations activate the kinase activity by a ligand-independent mechanism. Deletions in exon 19 and the point mutation of L858R are common activating mutations and these ‘classical’ mutations are associated with sensitivity to gefitinib and erlotinib in patients with NSCLC. T790M is a secondary point mutation found in tumors that were previously responsive to these agents, but have developed acquired resistance. Adapted from Kumar et al., 2008.

Similar articles

See all similar articles

Cited by 277 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback